spacer
home > ict > summer 2019 > therapeutic oncology and the road ahead
PUBLICATIONS
International Clinical Trials

Therapeutic Oncology and the Road Ahead




ICT: What trends are you seeing in therapeutic oncology?

Dr Tim Williams: We are seeing significant interest in the application of remote, digital patient-reported outcomes measurement (PROMs) to enhance routine cancer care in the UK. There is growing awareness of the importance in quality of life as more people live with and beyond cancer, as well as a drive for new approaches to support cancer service delivery and better care for patients over the long term, focusing on acute treatment at a time when the workforce faces increased pressure.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Dr Tim Williams is the Co-Founder and CEO of My Clinical Outcomes (MCO), a clinical technology platform that automates the collection and analysis of PROMs in routine clinical practice. Tim previously worked as an NHS doctor and Strategy Consultant and has a keen interest in how technology can help improve healthcare services. MCO is in use at over 70 UK public and private hospitals in a range of conditions and specialties and is now working on several innovative projects helping to support the care of cancer patients in the NHS.


Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 
Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement